Get the app
US › Healthcare

Eikon Therapeutics, Inc. Common Stock (EIKN)

US · Healthcare · Biotechnology

$7.42-1.59%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-88.4M
EPS
$-1.63
EPS estimate
$-1.61

EPS came in at -1.63 against a street estimate of -1.61 — a miss of 1.2%.

Key statistics

Market cap
$379.7M
Forward P/E
0.0
P/B
1.04
Book value
$8.62
EPS (TTM)
$-8.51
52-week high
$17.40
52-week low
$6.45
50-day MA
$9.45
200-day MA
$10.68

Analyst view

Analysts rate Eikon Therapeutics, Inc. Common Stock a buy (5 buy, 0 hold, 1 sell out of 6) with an average price target of $24.60.

Shareholding

Insiders
17.38%
Institutions
69.60%

Largest institutional holders

FundStake
FMR Inc9.22%
BlackRock Inc7.90%
Foresite Capital Management IV, LLC3.59%
Merck & Co Inc3.08%
T. Rowe Price Investment Management,Inc.2.95%
Foresite Capital Management V, LLC2.44%
Capital World Investors2.17%
T. Rowe Price Associates, Inc.1.86%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eikon Therapeutics, Inc. Common Stock — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.